(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
21 December 2006 (21.12.2006)

PCT

(10) International Publication Number
WO 2006/134125 A1

(51) International Patent Classification:
A61K 39/12 (2006.01) *C12N 15/48* (2006.01)
C12N 15/12 (2006.01) *C12N 15/52* (2006.01)

(21) International Application Number:
PCT/EP2006/063198

(22) International Filing Date: 14 June 2006 (14.06.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/690,094 14 June 2005 (14.06.2005) US

(71) Applicant *(for all designated States except US)*: **CYTOS BIOTECHNOLOGY AG** [—/CH]; Wagistrasse 25, CH-8952 Schlieren (CH).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **BACHMANN, Martin** [CH/CH]; Cytos Biotechnology AG, Goldackerweg 8, CH-8472 Seuzach (CH). **TISSOT, Alain** [CH/CH]; Cytos Biotechnology AG, Segantinistrasse 35, CH-8049 Zürich (CH). **JEGERLEHNER, Andrea** [CH/CH]; Josefstrasse 162, CH-8004 Zürich (CH). **SAUDAN, Philippe** [CH/CH]; Durrenrainstrasse 20, CH-8422 Pfungen (CH). **ZOU, Yu** [CN/CH]; Alte Zürcherstrasse 35, CH-8903 Birmensdorf (CH). **SCHMITZ, Nicole** [DE/CH]; Bahnhofstrasse 104, CH-8902 Urdorf (CH). **HUBER, Adrian** [CH/CH]; Eschergutweg 5, CH-8049 Zürich (CH). **MARTIN, Stephen** [NZ/NZ]; 30 Tweed Street, Roslyn, Dunedin, New Zealand (NZ). **HINTON, Heather** [GB/CH]; Hofstrasse 21, CH-6300 Zug (CH).

(74) Agent: **SPERRLE, Martin**; Cytos Biotechnology AG, Director IP & Legal Affairs, Wagistrasse 25, CH-8952 Schlieren (CH).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*
— *of inventorship (Rule 4.17(iv))*

Published:
— *with international search report*
— *with sequence listing part of description published separately in electronic form and available upon request from the International Bureau*

(48) Date of publication of this corrected version:
10 May 2007

(15) Information about Correction:
see PCT Gazette No. 19/2007 of 10 May 2007

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: ANTIGEN CONJUGATES AND USES THEREOF

(57) Abstract: The present invention is in the fields of medicine, public health, immunology, molecular biology and virology. The invention provides composition comprising a virus-like particle (VLP) linked to at least one antigen of the invention, wherein said antigen of the invention is CCR5 of the invention, gastrin of the invention, CXCR4 of the invention, CETP of the invention or C5a of the invention. The invention also provides a process for producing the composition. The compositions of this invention are useful in the production of vaccines, in particular, for the treatment of diseases in which the antigen of the invention mediates, or contributes to the condition, particularly for the treatment of AIDS, gastrointestinal cancers, coronary heart diseases or inflammatory diseases. Moreover, the compositions of the invention induce efficient immune responses, in particular antibody responses. Furthermore, the compositions of the invention are particularly useful to efficiently induce self-specific immune responses within the indicated context.

WO 2006/134125 A1